SCHEDULE 13G: Magnetar Entities Disclose 7.53% Stake in Translational Development Acquisition Corp.

Sentiment:

Schedule 13G Filing


Magnetar Financial LLC and its affiliated entities have disclosed a beneficial ownership of 7.53% in Translational Development Acquisition Corp., totaling 1.3 million Class A ordinary shares.

Summary

  • Magnetar Financial LLC, Magnetar Capital Partners LP, Supernova Management LLC, and David J. Snyderman (collectively, the "Reporting Persons") have filed a Schedule 13G.
  • The filing discloses beneficial ownership of 1,300,000 Class A ordinary shares of Translational Development Acquisition Corp.
  • This ownership represents approximately 7.53% of the issuer's total outstanding Class A ordinary shares, based on 17,250,000 shares outstanding as of December 24, 2024.
  • The shares are held across various Magnetar Funds, including Constellation Master Fund (299,000 shares), Lake Credit Fund (234,000 shares), Structured Credit Fund (208,000 shares), Xing He Master Fund (195,000 shares), Alpha Star Fund (130,000 shares), Purpose Credit Fund (117,000 shares), SC Fund (91,000 shares), and Purpose Credit Fund T (26,000 shares).
  • The acquisition of shares was made in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects. It is a neutral regulatory filing.

Future Outlook

NA

Management Comments

  • The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business.
  • The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Translational Development Acquisition Corp.
  • The acquisition was not in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

NA

Stakeholder Impact

  • Shareholders: Provides transparency regarding significant institutional ownership, which may be viewed as a vote of confidence or as a potential precursor to future engagement, although the filing explicitly states a passive investment intent.

Key Dates

DateDescription
2022-12-22Date of Limited Power of Attorney granted by David J. Snyderman.
2024-12-24Approximate date of 17,250,000 shares outstanding for Translational Development Acquisition Corp., as per issuer's Form 8-K.
2024-12-31Date of event which requires the filing of this Schedule 13G statement.
2025-01-29Date of filing of the Schedule 13G statement and Joint Filing Agreement.

Keywords

Translational Development Acquisition Corp., Magnetar Financial LLC, Schedule 13G, Beneficial Ownership, Class A ordinary share, Investment Adviser, SEC Filing, Passive Investment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.